| XLS |
|
|
|
| ||
|
€ million |
Q1 – 2012 |
Q1 – 2011* | ||
| ||||
|
Sales |
2,563.9 |
2,477.5 | ||
|
Royalty, license and commission income |
81.1 |
86.2 | ||
|
Total revenues |
2,644.9 |
2,563.8 | ||
|
|
|
| ||
|
Cost of sales |
–748.7 |
–639.0 | ||
|
Gross profit |
1,896.2 |
1,924.8 | ||
|
|
|
| ||
|
Marketing and selling expenses |
–586.6 |
–590.0 | ||
|
Royalty, license and commission expenses |
–120.0 |
–111.3 | ||
|
Administration expenses |
–135.8 |
–129.9 | ||
|
Other operating expenses and income |
–144.6 |
62.9 | ||
|
Research and development |
–381.8 |
–378.8 | ||
|
Amortization of intangible assets |
–216.3 |
–248.2 | ||
|
Investment result |
– |
– | ||
|
Operating result (EBIT) |
311.2 |
529.5 | ||
|
|
|
| ||
|
Financial result |
–65.1 |
–68.3 | ||
|
Profit before income tax |
246.1 |
461.2 | ||
|
|
|
| ||
|
Income tax |
–69.4 |
–117.0 | ||
|
Profit after tax |
176.6 |
344.2 | ||
|
|
|
| ||
|
of which attributable to Merck KGaA shareholders |
174.2 |
341.1 | ||
|
of which non-controlling interest |
2.4 |
3.1 | ||
|
|
|
| ||
|
Earnings per share (in €) |
|
| ||
|
basic |
0.80 |
1.57 | ||
|
diluted |
0.80 |
1.57 | ||